A phase II study of the oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma

E Van den Neste; M Andre; G Thomas; A Stamatoullas; C Haioun; A Belhabri; O Reman; O Casasnovas; H Ghesquieres; G Verhoef; Marie-José Claessen; HA Poirel; MC Copin; R Dubois; P Vandenberghe; IA Stoian; AS Cottereau; S Bailly; L Knoops; F Morschhauser

doi:10.3324/haematol.2017.180554

A phase II study of the oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma

E Van den Neste, M Andre, G Thomas, A Stamatoullas, C Haioun, A Belhabri, O Reman, O Casasnovas, H Ghesquieres, G Verhoef, Marie-José Claessen, HA Poirel, MC Copin, R Dubois, P Vandenberghe, IA Stoian, AS Cottereau, S Bailly, L Knoops, F Morschhauser

Hematology

Research output: Contribution to journal › Article › Academic › peer-review

32 Citations (Scopus)

3 Downloads (Pure)

Original language	Undefined/Unknown
Pages (from-to)	840-848
Number of pages	9
Journal	Haematologica
Volume	103
Issue number	5
DOIs	https://doi.org/10.3324/haematol.2017.180554
Publication status	Published - 2018

Access to Document

10.3324/haematol.2017.180554

REPUB_106229-OA.pdfFinal published version, 768 KB

http://hdl.handle.net/1765/106229

Cite this

Van den Neste, E., Andre, M., Thomas, G., Stamatoullas, A., Haioun, C., Belhabri, A., Reman, O., Casasnovas, O., Ghesquieres, H., Verhoef, G., Claessen, M-J., Poirel, HA., Copin, MC., Dubois, R., Vandenberghe, P., Stoian, IA., Cottereau, AS., Bailly, S., Knoops, L., & Morschhauser, F. (2018). A phase II study of the oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma. Haematologica, 103(5), 840-848. https://doi.org/10.3324/haematol.2017.180554

@article{7d919dce5b2343d39d0fd63f1a071c6f,

title = "A phase II study of the oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma",

author = "{Van den Neste}, E and M Andre and G Thomas and A Stamatoullas and C Haioun and A Belhabri and O Reman and O Casasnovas and H Ghesquieres and G Verhoef and Marie-Jos{\'e} Claessen and HA Poirel and MC Copin and R Dubois and P Vandenberghe and IA Stoian and AS Cottereau and S Bailly and L Knoops and F Morschhauser",

year = "2018",

doi = "10.3324/haematol.2017.180554",

language = "Undefined/Unknown",

volume = "103",

pages = "840--848",

journal = "Haematologica",

issn = "0390-6078",

publisher = "Ferrata Storti Foundation",

number = "5",

}

Van den Neste, E, Andre, M, Thomas, G, Stamatoullas, A, Haioun, C, Belhabri, A, Reman, O, Casasnovas, O, Ghesquieres, H, Verhoef, G, Claessen, M-J, Poirel, HA, Copin, MC, Dubois, R, Vandenberghe, P, Stoian, IA, Cottereau, AS, Bailly, S, Knoops, L & Morschhauser, F 2018, 'A phase II study of the oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma', Haematologica, vol. 103, no. 5, pp. 840-848. https://doi.org/10.3324/haematol.2017.180554

TY - JOUR

T1 - A phase II study of the oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma

AU - Van den Neste, E

AU - Andre, M

AU - Thomas, G

AU - Stamatoullas, A

AU - Haioun, C

AU - Belhabri, A

AU - Reman, O

AU - Casasnovas, O

AU - Ghesquieres, H

AU - Verhoef, G

AU - Claessen, Marie-José

AU - Poirel, HA

AU - Copin, MC

AU - Dubois, R

AU - Vandenberghe, P

AU - Stoian, IA

AU - Cottereau, AS

AU - Bailly, S

AU - Knoops, L

AU - Morschhauser, F

PY - 2018

Y1 - 2018

U2 - 10.3324/haematol.2017.180554

DO - 10.3324/haematol.2017.180554

M3 - Article

VL - 103

SP - 840

EP - 848

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 5

ER -